Ann: Invion appoints Mr Brett Heading as Chairman, page-12

yes matakus, these companies may go deeper into debt but at least their market cap rises when they hit milestones, Invion seems to - against all logic - drop even when drug development is progressed.

I know having 3 phase 2s is a good thing because more is better. The other hand says could invion have taken too much on? Was their burn rate too large? Did they pick the right people to run their trials?

Was the CEO caught between giving no news and giving bad news as results were delayed?

Will we see full dosage ann. of nadolol in May.... or just deathly silence.

I suppose while I am still positive about their assets, management should just be a little bit more on the front foot with estimates and talking to shareholders.